Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis Inc. (NASDAQ: CRIS) is a biotechnology company dedicated to the development and commercialization of groundbreaking drug candidates aimed at treating human cancers. Established as a significant player in the biotech sector, Curis is renowned for its focus on immuno-oncology and precision oncology therapeutic areas.
Core Business and Pipeline
Curis's pipeline is robust, featuring a number of promising drug candidates. One of its leading drugs is Emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor currently undergoing clinical trials. The trials include the Phase 1/2 TakeAim Lymphoma study, which targets hematologic malignancies such as non-Hodgkin's lymphoma, and the Phase 1/2 TakeAim Leukemia study aimed at acute myeloid leukemia and myelodysplastic syndrome. Emavusertib has already received Orphan Drug Designation from the U.S. Food and Drug Administration.
Curis is also investigating other candidates such as CUDC-907, which focuses on relapsed or refractory diffuse large B-cell lymphoma with alterations in the MYC oncogene, and other small molecule antagonists like CA-170 and CA-327, designed to inhibit pathways such as PD1, VISTA, and TIM3.
Collaborations & Partnerships
Curis has forged a strategic collaboration with Aurigene, granting it exclusive licenses to several promising molecules. This partnership enhances Curis's ability to innovate in the areas of immuno-oncology and precision oncology, specifically with oral small molecule antagonists. Additionally, Curis has licensed its rights to Erivedge® to Genentech, which is commercializing the drug for advanced basal cell carcinoma under the Roche Group.
Recent Achievements and Financial Condition
Curis has recently presented data from multiple clinical studies at prestigious conferences such as the American Society of Hematology (ASH) and the European Hematology Association (EHA), showcasing promising results from its ongoing trials. The company reported a net loss of $47.4 million for the year ended December 31, 2023, but continues to maintain a strong cash position with $56.3 million in cash, cash equivalents, and investments.
Curis's ongoing research and development efforts are backed by substantial funding and strategic partnerships, enabling the company to sustain its operations and advance its pipeline into the year 2025.
For more information, visit Curis's website at www.curis.com.
Curis, Inc. (NASDAQ: CRIS) announced the approval of inducement stock options on January 3, 2022, granting 224,700 shares to eleven new employees. The options have a 10-year term, with vesting over four years based on continued employment. Each grant's exercise price matches the stock's closing price on the grant date, incentivizing new hires as part of the company's growth strategy in cancer therapeutics. Curis focuses on innovating treatments, particularly in immuno-oncology, with several clinical trials underway for its drug candidates.
Curis, Inc. (NASDAQ: CRIS) announced positive clinical data from its ongoing Phase 1/2 study of CA-4948, an IRAK-4 inhibitor, for treating relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). As of December 16, 2021, CA-4948 was well-tolerated, with no dose-limiting toxicities reported, and showed promising anti-cancer activity with a 40% complete response rate in AML patients with specific mutations. Curis also reported initial positive safety data for CI-8993, a monoclonal antibody targeting VISTA, currently in Phase 1 trials for solid tumors.
Curis, Inc. (NASDAQ: CRIS) announced the appointment of three new executives to enhance its management team as of January 3, 2022. Felix Geissler, M.D., Ph.D., becomes Vice President of Medical Affairs; Kimberly Steinmann, M.D., Vice President of Clinical Development; and Dora Ferrari, Vice President of Clinical Operations. These appointments aim to bolster internal capabilities for advancing clinical drug candidates CA-4948 and CI-8993. The company is focused on developing innovative cancer therapeutics and has collaborations for its drug candidates, including ongoing trials.
Curis, Inc. (NASDAQ: CRIS) announced that CEO James Dentzer will present at the H.C. Wainwright BioConnect Conference on January 10, 2022, starting at 7:00 a.m. ET. The presentation will be available for on-demand viewing afterward. A live webcast can be viewed in the Investors section of Curis' website and will remain accessible for 90 days. Curis focuses on developing cancer therapeutics, including collaborations on various oncology treatments, such as the IRAK4 inhibitor CA-4948, currently in trials for non-Hodgkin lymphoma and acute myeloid leukemia.
Curis, Inc. (NASDAQ: CRIS) has been added to the Nasdaq Biotechnology Index and the iShares Biotechnology ETF, effective before market open on December 20, 2021. Curis focuses on innovative cancer therapeutics, with ongoing clinical trials for several drug candidates, including CA-4948, which has received Orphan Drug Designation for acute myeloid leukemia. The company collaborates with Aurigene and ImmuNext, and their partnership with Genentech commercializes Erivedge for advanced basal cell carcinoma.
Curis, Inc. (NASDAQ: CRIS) announced the appointment of John A. Hohneker, M.D., to its Board of Directors on Dec. 6, 2021. Dr. Hohneker brings over 30 years of biopharmaceutical experience, previously serving as President and CEO of Anokion SA and in leadership roles at Novartis. His expertise will support Curis in accelerating drug candidates, particularly the first-in-class IRAK4 inhibitor, CA-4948, currently in clinical trials for various cancers. This appointment is seen as pivotal for Curis's future growth and potential commercialization of its therapies.
Curis (CRIS) announced its Q3 2021 financial results, reporting a net loss of $11.1 million or $0.12 per share, compared to a loss of $6.0 million for Q3 2020. Revenues grew to $3.0 million from $2.7 million year-over-year. The company continues to advance its clinical trials for CA-4948 in AML, MDS, and B cell cancers, with a significant update expected in January 2022. Operating expenses increased to $13.1 million due to higher R&D costs. As of September 30, 2021, Curis had $149.8 million in cash, ensuring planned operations into 2024.
Curis, Inc. (NASDAQ: CRIS) announced new preclinical data for its investigational monoclonal antibody, CI-8993, at the Society for Immunotherapy of Cancer's 36th Annual Meeting. CI-8993 targets the immune checkpoint molecule VISTA, with a study conducted in collaboration with the Olivia Newton-John Cancer Research Institute confirming its binding properties. Future plans include a clinical trial involving patients with solid tumors. This research aligns with Curis's commitment to advancing cancer therapies and supports ongoing development in immuno-oncology.
Curis, Inc. (NASDAQ: CRIS) announced the first patient has been dosed in the Phase 1/2 clinical trial of CA-4948, an IRAK4 kinase inhibitor, aimed at patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). This study will evaluate CA-4948 in combination with azacitidine and venetoclax, targeting improved treatment options for patients ineligible for intensive chemotherapy. Initial monotherapy results have been promising, and CA-4948 has received Orphan Drug Designation from the FDA.
Curis, Inc. (NASDAQ: CRIS) is set to release its third quarter 2021 financial results on November 9, 2021, after market close. Management will host a conference call at 4:30 PM ET to discuss the results. Curis focuses on innovative cancer therapeutics, holding exclusive licenses for several small molecule antagonists and conducting clinical trials for drugs like CA-4948 in non-Hodgkin's lymphoma and acute myeloid leukemia. Key collaborations include partnerships with Aurigene and Genentech for drug development and commercialization.
FAQ
What is the current stock price of Curis (CRIS)?
What is the market cap of Curis (CRIS)?
What is Curis Inc.'s focus in the biotechnology sector?
What are some of the key drug candidates in Curis's pipeline?
What significant collaborations does Curis have?
What is the current status of Emavusertib's clinical trials?
How is Curis performing financially?
What recent achievements has Curis reported?
What is the significance of Curis's collaboration with Aurigene?
What role does Genentech play in Curis's portfolio?
What are Curis's future plans for its drug pipeline?
Where can I find more information about Curis Inc.?
